Metabolic and pharmacokinetic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor after intragastric administration of nanoparticle formulations by liquid chromatography coupled with tandem mass spectrometry

被引:48
作者
Li, Rui [1 ]
Qiao, Xue [1 ]
Li, Qingyan [2 ]
He, Rong [3 ]
Ye, Min [1 ]
Xiang, Cheng [1 ]
Lin, Xionghao [1 ]
Guo, Dean [1 ]
机构
[1] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
[2] Civil Aviat Adm China, Civil Aviat Med Ctr, Beijing 100123, Peoples R China
[3] Peking Univ Third Hosp, Dept Cardiol, Beijing 100191, Peoples R China
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2011年 / 879卷 / 26期
关键词
Curcumin; Curcuminoids; LC/MS/MS; Nanoparticle; Pharmacokinetics; Tumor; FACTOR-KAPPA-B; IN-VITRO; GENE-EXPRESSION; CELL LINES; SUPPRESSION; PATHWAY; KINASE; PLASMA; DIFERULOYLMETHANE; ACTIVATION;
D O I
10.1016/j.jchromb.2011.07.042
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This paper aims to investigate the metabolism and pharmacokinetics of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor. To improve water solubility, nanoparticle formulations were prepared as curcuminoids-loaded solid lipid nanoparticles (curcuminoicls-SLNs) and curcumin-loaded solid lipid nanoparticles (curcumin-SLNs). After intragastric administration to tumor-bearing ICR mice, the plasma and tumor samples were analyzed by liquid chromatography with ion trap mass spectrometry. We discovered that curcuminoids were mainly present as glucuronides in plasma, whereas in free form in tumor tissue. A validated LC/MS/MS method was established to determine the three free curcuminoids in tumor homogenate. Samples were separated on a Zorbax SB-C-18 column, eluted with acetonitrile-water (containing 0.1% formic acid), and detected by TSQ Quantum triple quadrupole mass spectrometer in selected reaction monitoring mode. The method showed good linearity (r(2) = 0.997-0.999) over wide dynamic ranges (2-6000 ng/mL). Variations within- and between-batch never exceeded 11.2% and 13.4%, respectively. The extraction recovery rates ranged from 78.3% to 87.7%. The pharmacokinetics of curcuminoids in mice tumor fit two-compartment model and first order elimination. For curcumin-SLNs group, the dosing of 250 mg/kg of curcumin resulted in AUC((0-48h)) of 2285 ng h/mL and C-max of 209 ng/mL. For curcuminoids-SLNs group, the dosing equivalent to 138 mg/kg of curcumin resulted in higher tumor concentrations (AUC= 2811 ng h/mL. C-max = 285 ng/mL). It appeared that co-existing curcuminoids improved the bioavailability of curcumin. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:2751 / 2758
页数:8
相关论文
共 42 条
[31]   Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane) [J].
Sandur, Santosh K. ;
Ichikawa, Haruyo ;
Pandey, Manoj K. ;
Kunnumakkara, Ajaikumar B. ;
Sung, Bokyung ;
Sethi, Gautam ;
Aggarwal, Bharat B. .
FREE RADICAL BIOLOGY AND MEDICINE, 2007, 43 (04) :568-580
[32]   Curcumin, demethtoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism [J].
Sandur, Santosh K. ;
Pandey, Manoj K. ;
Sung, Bokyung ;
Ahn, Kwang Seok ;
Murakatni, Akira ;
Sethi, Gautarn ;
Limtrakul, Pornngarm ;
Badmaev, Vladimir ;
Aggarwal, Bharat B. .
CARCINOGENESIS, 2007, 28 (08) :1765-1773
[33]   Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance [J].
Sharma, RA ;
Euden, SA ;
Platton, SL ;
Cooke, DN ;
Shafayat, A ;
Hewitt, HR ;
Marczylo, TH ;
Morgan, B ;
Hemingway, D ;
Plummer, SM ;
Pirmohamed, M ;
Gescher, AJ ;
Steward, WP .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6847-6854
[34]   Curcumin: The story so far [J].
Sharma, RA ;
Gescher, AJ ;
Steward, WP .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (13) :1955-1968
[35]   Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor KB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway [J].
Siwak, DR ;
Shishodia, S ;
Aggarwal, BB ;
Kurzrock, R .
CANCER, 2005, 104 (04) :879-890
[36]   Formulation and characterization of curcuminoids loaded solid lipid nanoparticles [J].
Tiyaboonchai, Waree ;
Tunpradit, Watcharaphorn ;
Plianbangchang, Pinyupa .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 337 (1-2) :299-306
[37]  
US FDA, 2001, GUID IND BIOAN METH
[38]   Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects [J].
Vareed, Shaiju K. ;
Kakarala, Madhuri ;
Ruffin, Mack T. ;
Crowell, James A. ;
Normolle, Daniel P. ;
Djuric, Zora ;
Brenner, Dean E. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (06) :1411-1417
[39]   Determination of two C21 steroidal glycosides of Baishouwu and their metabolites in mice plasma and tumor homogenate by liquid chromatography-tandem mass spectrometry [J].
Xu, Wen ;
Shan, Lei ;
Liu, Xiaohua ;
Li, Haiyun ;
Hu, Liwei ;
Zhang, Weidong .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 876 (02) :203-210
[40]   Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth [J].
Yallapu, Murali M. ;
Maher, Diane M. ;
Sundram, Vasudha ;
Bell, Maria C. ;
Jaggi, Meena ;
Chauhan, Subhash C. .
JOURNAL OF OVARIAN RESEARCH, 2010, 3